DOI 10.1212/nxi.0000000000000050
Occurrence of hemolytic anemia in patients with GBS treated with high-dose IVIg.
Аннотация
OBJECTIVE
We describe an underrecognized side effect of high-dose IV immunoglobulin (IVIg), hemolytic anemia.
BACKGROUND
There are no established guidelines on treating patients with Guillain-Barré syndrome (GBS) who relapse or do not improve after a standard course of treatment (IVIg or plasma exchange). Some centers will opt for a second course of the initial treatment. There is an ongoing trial of a second course of IVIg in patients with severe GBS.
METHODS
We retrospectively reviewed 4 patients with severe GBS who received high-dose IVIg. One patient inadvertently received a high dose of IVIg for Miller Fisher syndrome. All patients received a total of at least 2 courses of the standard dose of IVIg (total >4 g/kg). We review their clinical course and side effects.
RESULTS
All patients with non-O blood types developed clinically significant hemolytic anemia requiring blood transfusion.
CONCLUSION
Hemolytic anemia may limit doses of IVIg for treatment of severe GBS in patients with non-O blood types.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.